These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 11251623

  • 1. Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
    Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M.
    Clin Exp Allergy; 2001 Feb; 31(2):219-25. PubMed ID: 11251623
    [Abstract] [Full Text] [Related]

  • 2. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
    Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, Nizankowska E, Isakson PC, Mejza F, Lefkowith JB, Dahlén SE, Szczeklik A, Murray JJ, Dahlén B.
    J Allergy Clin Immunol; 2003 May; 111(5):1116-21. PubMed ID: 12743579
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients.
    Martín-García C, Hinojosa M, Berges P, Camacho E, García-Rodriguez R, Alfaya T.
    J Investig Allergol Clin Immunol; 2003 May; 13(1):20-5. PubMed ID: 12861847
    [Abstract] [Full Text] [Related]

  • 6. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
    Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z.
    J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA.
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [Abstract] [Full Text] [Related]

  • 9. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
    Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A.
    Arch Dermatol; 2003 Dec; 139(12):1577-82. PubMed ID: 14676074
    [Abstract] [Full Text] [Related]

  • 10. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
    Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, Yao SL.
    Ann Intern Med; 2000 Jul 04; 133(1):1-9. PubMed ID: 10877734
    [Abstract] [Full Text] [Related]

  • 11. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma.
    Martín-García C, Hinojosa M, Berges P, Camacho E, García-Rodriguez R, Alfaya T, Iscar A.
    Chest; 2002 Jun 04; 121(6):1812-7. PubMed ID: 12065343
    [Abstract] [Full Text] [Related]

  • 12. COX-1 sparing drugs in aspirin-sensitive asthma.
    Picado C, Valero A.
    Clin Exp Allergy; 2001 Feb 04; 31(2):179-81. PubMed ID: 11251618
    [No Abstract] [Full Text] [Related]

  • 13. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions.
    Quiralte J, Sáenz de San Pedro B, Florido JJ.
    Ann Allergy Asthma Immunol; 2002 Jul 04; 89(1):63-6. PubMed ID: 12141722
    [Abstract] [Full Text] [Related]

  • 14. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
    Stevenson DD, Simon RA.
    J Allergy Clin Immunol; 2001 Jul 04; 108(1):47-51. PubMed ID: 11447381
    [Abstract] [Full Text] [Related]

  • 15. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, Dagenais GR.
    Circulation; 2004 Aug 24; 110(8):934-9. PubMed ID: 15302800
    [Abstract] [Full Text] [Related]

  • 16. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma.
    Mita H, Endoh S, Kudoh M, Kawagishi Y, Kobayashi M, Taniguchi M, Akiyama K.
    Allergy; 2001 Nov 24; 56(11):1061-7. PubMed ID: 11703219
    [Abstract] [Full Text] [Related]

  • 17. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
    Woessner KM, Simon RA, Stevenson DD.
    Ann Allergy Asthma Immunol; 2004 Oct 24; 93(4):339-44. PubMed ID: 15521369
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The importance of COX-2 inhibition for aspirin induced asthma.
    Bennett A.
    Thorax; 2000 Oct 24; 55 Suppl 2(Suppl 2):S54-6. PubMed ID: 10992560
    [No Abstract] [Full Text] [Related]

  • 20. [No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain].
    Einecke D.
    MMW Fortschr Med; 2002 Nov 14; 144(46):68. PubMed ID: 12534087
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.